StockData
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT) stock

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3028% above fair value
$60.23−0.13 (-0.22%)

Close on Nov 18, 2026Market cap $5.03BP/E –Yield –

PTC Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

PTC Therapeutics's operating income for the twelve months ending Sep 30, 2026 was $147.70M, down 81.0% year over year. For fiscal 2025 it was $866.94M. The highest annual figure on record is $866.94M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$866.94M–
FY2024Dec 31, 2024-$302.57M–
FY2023Dec 31, 2023-$439.50M–
FY2022Dec 31, 2022-$447.41M–
FY2021Dec 31, 2021-$374.44M–
FY2020Dec 31, 2020-$431.77M–
FY2019Dec 31, 2019-$241.16M–
FY2018Dec 31, 2018-$115.69M–
FY2017Dec 31, 2017-$64.29M–
FY2016Dec 31, 2016-$132.06M–
FY2015Dec 31, 2015-$167.13M–
FY2014Dec 31, 2014-$99.41M–
FY2013Dec 31, 2013-$45.40M–
FY2012Dec 31, 2012-$26.81M-187.7%
FY2011Dec 31, 2011$30.58M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$25.11M+732.7%
Q2 FY2026Jun 30, 2026$148.98M–
Q1 FY2026Mar 31, 2026$44.96M-95.4%
Q4 FY2025Dec 31, 2025-$71.35M–
Q3 FY2025Sep 30, 2025$3.02M–
Q2 FY2025Jun 30, 2025-$34.96M–
Q1 FY2025Mar 31, 2025$970.23M–
Q4 FY2024Dec 31, 2024-$162.39M-2890.2%
Q3 FY2024Sep 30, 2024-$54.51M–
Q2 FY2024Jun 30, 2024-$40.22M–
Q1 FY2024Mar 31, 2024-$45.45M–
Q4 FY2023Dec 31, 2023$5.82M–
Q3 FY2023Sep 30, 2023-$118.16M–
Q2 FY2023Jun 30, 2023-$209.54M–
Q1 FY2023Mar 31, 2023-$117.62M–
Q4 FY2022Dec 31, 2022-$200.34M–
Q3 FY2022Sep 30, 2022-$68.19M–
Q2 FY2022Jun 30, 2022-$92.36M–
Q1 FY2022Mar 31, 2022-$86.52M–
Q4 FY2021Dec 31, 2021-$84.73M–
Q3 FY2021Sep 30, 2021-$93.08M–
Q2 FY2021Jun 30, 2021-$98.49M–
Q1 FY2021Mar 31, 2021-$98.15M–
Q4 FY2020Dec 31, 2020-$96.37M–
Q3 FY2020Sep 30, 2020-$55.13M–
Q2 FY2020Jun 30, 2020-$187.27M–
Q1 FY2020Mar 31, 2020-$92.99M–
Q4 FY2019Dec 31, 2019-$72.78M–
Q3 FY2019Sep 30, 2019-$60.48M–
Q2 FY2019Jun 30, 2019-$38.76M–
Q1 FY2019Mar 31, 2019-$69.14M–
Q4 FY2018Dec 31, 2018-$45.14M-927.9%
Q3 FY2018Sep 30, 2018-$48.23M–
Q2 FY2018Jun 30, 2018-$5.57M–
Q1 FY2018Mar 31, 2018-$16.74M–
Q4 FY2017Dec 31, 2017$5.45M–
Q3 FY2017Sep 30, 2017-$30.89M–
Q2 FY2017Jun 30, 2017-$12.50M–
Q1 FY2017Mar 31, 2017-$26.36M–
Q4 FY2016Dec 31, 2016-$24.99M–

More PTC Therapeutics figures

See a number that looks wrong?